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Sorafenib, an orally available multikinase inhibitor, combined with radiation has shown potential as an
anticancer treatment in an in vitro and in vivo colon cancer model. In this study, we investigated the mech-
anism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. The effects of
sorafenib on radiation-induced cytotoxicity of DLD-1 and HT-29 were evaluated via clonogenic assay. The
impact of sorafenib on radiation-induced cell cycle kinetics and on apoptosis was analyzed using flow cyto-
metry. Cyclin B1 was examined by western blot. As a measure of DNA damage after treatment, γ-H2AX
foci and nuclear fragmentation were determined as a function of time after irradiation plus sorafenib com-
bination. Tumor growth delay was used to evaluate the effects of sorafenib on in vivo radiation-induced
cytotoxicity. Exposure of each cell line to sorafenib combined with irradiation resulted in an increased radi-
ation-induced cytotoxicity with dose enhancement factors at a surviving fraction of 0.37 ranging from 1.13
to 1.76. Sorafenib strengthened radiation-induced accumulation of tumor cells in the G2-M phase with atte-
nuated expression of cyclin B1, but had no effect on radiation-induced apoptosis. Exposure to sorafenib and
radiation resulted in a greater number of remaining γ-H2AX foci and fragmented nuclei than radiation
alone. In vivo tumor xenograft study confirmed that administration of sorafenib results in significant tumor
growth inhibition when combined with radiation. These results indicate that sorafenib enhances radiation-
induced cytotoxicity in colorectal cancer and suggest that the mechanism is associated with delaying repair
of radiation-induced DNA damage and down-regulation of cyclin B1.
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INTRODUCTION
Radical surgery has been the mainstay of management of
colorectal cancer. In postoperative adjuvant settings, radio-
therapy with chemotherapy was previously believed to
reduce local failure and distant metastasis, thereby improv-
ing the clinical outcomes of patients with high risk factors
[1–3]. Unlike in the US, European investigators have con-
tinuously favored a short course preoperative radiotherapy
that has been shown to improve local control in clinical
studies [4–6]. The German Rectal Cancer Trial Study
Group demonstrated that preoperative chemoradiotherapy
(CRT), as compared with postoperative CRT, improved
local control and was associated with reduced toxicity, but
did not improve overall survival [7]. Therefore, the standard
adjuvant treatment was shifted from postoperative CRT to
preoperative CRT in mid- and distal rectal cancers.
Pathologic treatment response or downstaging after neoad-
juvant CRT seems to have a significant clinical implication
that pathologic response after preoperative CRT may be
closely related to prognoses [8, 9]. Therefore, an enhanced
radiation response is necessary for better pathologic re-
sponse after preoperative CRT. A promising strategy is to
use molecular targeted agents.
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Sorafenib is an orally available multikinase inhibitor that
targets kinases of wild-type B-Raf, mutant V559EB-Raf,
and C-Raf, blocking tumor growth. Furthermore, sorafenib
shows potent inhibition of receptor tyrosine kinases
involved in angiogenesis, including human vascular endo-
thelial growth factor receptors-2 and -3, as well as the
platelet-derived growth factor receptor-β [10]. Sorafenib has
been shown to inhibit the proliferation of a variety of
human cancer cell lines and xenograft models. A series of
clinical studies tested the antineoplastic potency of sorafe-
nib in cancer patients. Therein, sorafenib prolonged
progression-free and overall survival in phase III clinical
studies of patients with metastatic renal cell carcinoma or
advanced heaptocellular carcinoma, respectively [11, 12].
Moreover, preliminary data from a series of combination
studies with sorafenib and a variety of anti-cancer agents
for various solid tumor entities have been published [13].
Previous studies have shown sorafenib inhibited in vivo
tumor growth combined with radiation, but did not suggest
the mechanism in vitro [14, 15]. Subsequently, in this study
we attempted to investigate the mechanism of enhancement
of radiation-induced cytotoxicity by sorafenib using in vitro
and in vivo colorectal cancer models.
MATERIALS AND METHODS
Cell cultures and reagents
DLD-1 and HT-29 cells originated from colorectal adeno-
carcinomas were maintained in minimum essential medium
and Rosewell Park Memorial Institute media supplemented
with 10% fetal bovine serum, 100 U/ml penicillin and
0.1 mg/ml streptomycin. Cells were incubated at 37°C in a
5% CO2 humidified atmosphere, and the media were
replaced every 3–4 days. Sorafenib was provided by Bayer
Pharmaceutical Corporation (West Haven, CT, USA).
Clonogenic assay for radiation survival experiment
Log-phase cells were trypsinized, plated in triplicate per
data point into 25-cm2 cell culture flasks, and then permit-
ted to attach overnight. In the radiation survival experiment,
the cells were irradiated with graded doses of X-rays.
Tumor cells were irradiated with PRIMART (Siemens,
Berlin, Germany) with 6 megavoltage and a dose rate of 0.3
Gy/min. Immediately after irradiation, the cells were exposed
to a mock (DMSO) or to sorafenib for 72 h and then main-
tained in drug-free medium for 10 days to allow for the for-
mation of colonies and then stained with 0.5% crystal violet
in absolute methanol. The colonies were counted with a
cutoff value of 50 viable cells. We then calculated the dose
enhancement ratio (DER) as the dose (Gy) for the radiation
alone divided by the dose for radiation plus sorafenib
(normalized for drug toxicity) at a surviving fraction of
37% (D1).
Detection of cell cycle changes and apoptosis via
flow cytometry
The cells were exposed to single dose of X-rays and then
exposed to the appropriate concentrations of sorafenib or
vehicle. After additional 16, 24 and 48 h of incubation, the
cells were collected, fixed with 75% ethanol, and then incu-
bated with propidium iodide (PI) and RNase A. The number
of cells at each cell cycle was evaluated using the
FACSCalibur system (Becton Dickinson, San Jose, CA,
USA). To evaluate apoptotic cells, both adherent and non-
adherent cells were harvested at 12, 24 and 36 h after each
treatment. The experiments were performed using the Annexin
V-FITC Apoptosis Detection kit (Trevigen, Gaithersburg,
MD, USA) according to the manufacturer’s manual.
Immunofluorescent staining for γ-H2AX and
measurement of nuclear fragmentation
Cells were grown and treated in chamber slides. At speci-
fied timings, the cells were fixed in 4% paraformaldehyde
and incubated overnight with anti-γ-H2AX antibody
(Abcam, Cambridge, UK). Cells again were incubated in
the dark with an FITC-labeled secondary antibody for 1 h,
incubated in the dark with 4,6-diamidino-2-phenylindole
(DAPI), and cover slips were mounted with an antifade so-
lution. Detection of fluorescence and acquisition of images
were done with a Zeiss LSM 510 Meta confocal fluorescent
microscope. For each treatment condition, γ-H2AX foci
were determined in at least 100 cells. To visualize nuclear
fragmentation, cells were fixed with 4% paraformaldehyde,
and stained with DAPI followed by staining with α-tubulin.
A single field containing 300 cells was selected at random
for each treatment and photographed with epifluorescence.
Nuclear fragmentation was defined as the presence of two
or more distinct nuclear lobes within a single cell.
Western blotting
The cells were lysed in radioimmunoprecipitation assay
buffer, and protein concentrations were determined.
Proteins were denatured and fractionated on polyacrylamide
gels and then transferred to polyvinylidene difluoride mem-
branes after electrophoresis. After blocking, the filters were
incubated overnight in primary antibodies (Cyclin B1,
Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
filters were incubated with a horseradish peroxidase-
conjugated anti-mouse immunoglobulin as a secondary
antibody for 1 h at a 1:5,000 dilution. After three additional
washes, the filters were developed with an enhanced chemi-
luminescence system and scanned.
Tumor xenograft model and tumor growth delay
Five- to six-week-old nude mice were used in these studies.
They were housed in a specific pathogen-free (SPF) barrier
area at the Division of Laboratory Animal Medicine,
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College of Medicine, Yonsei University. The temperature
(22°C) and humidity (55%) were controlled constantly.
Water (RO water) and food (PMI) were supplied. The care
and use of laboratory animals in this study were based on
the Guidelines and Regulations for the Use and Care of
Animals at Yonsei University College of Medicine. DLD-1
cells were injected subcutaneously into the right hind leg.
Irradiation was performed using a linear accelerator with
animals restrained in a custom jig. To obtain tumor growth
curves, perpendicular diameter measurements of each
tumor were made every 2 days with digital calipers, and
volumes were calculated using the formula (L ×W ×W)/2.
Tumors were followed until the tumors of the radiation plus
sorafenib group reached a mean size of 2000 mm3. Growth
delay (GD) was calculated as the time for treated tumors to
reach an average volume of 2000 mm3 minus the time for
control tumors to reach 2000 mm3, with t = 0 defined as the
first day of treatment. EF was then determined as follows:
Enhancing factor (EF) = (GDSorafenib+RT – GDSorafenib)/GDRT.
Statistical analysis
Data were expressed as means ± standard error of mean
(SEM) and then analyzed with regard to statistical signifi-
cance using two-tailed Student’s t-tests. P-values < 0.05
were considered to be significant.
RESULTS
To determine the effects of sorafenib on radiation-induced
toxicity, clonogenic survival analysis was performed using
DLD-1 and HT-29 cell lines. In these studies, we used a
sorafenib concentration of 4 μmol/l, corresponding to an in-
hibitory concentration of 25% at a 72 h exposure to sorafe-
nib. To assess and characterize the radiation-enhancing
effects of sorafenib, the cells were exposed to graded doses
of radiation either with or without various concentrations of
sorafenib for 72 h. These cells were all then permitted to form
colonies in drug-free medium. The drug was administered im-
mediately after radiation treatment and dose-enhancing
ratio values were determined to be 1.76 and 1.13 at D1,
respectively (Fig. 1).
The effects of sorafenib on inhibition of cell cycle pro-
gression and modulation of interactions with radiation were
evaluated via flow cytometry in control (mock-treated),
sorafenib monotherapy, radiation alone, and the combin-
ation of radiation and sorafenib-treated groups. While radi-
ation induced accumulation of cells in the G2-M phase,
sorafenib showed no arrest in any specific cell phase.
Sorafenib treatment combined with radiation in the DLD-1
and HT-29 cells resulted in significantly increased and sus-
tained rates of G2-M phase cells, compared with that
observed as a result of radiotherapy alone in each cell line
(Fig. 2).
We further evaluated whether mechanisms of interaction
between sorafenib and radiation were involved in cell
killing mediated by apoptosis in HT-29 and DLD-1 cells.
Cells were harvested after 12, 24 and 36 h of exposure to
vehicle, sorafenib (4 μM), radiation (6 Gy) or combination
treatment. Apoptosis was measured with flow cytometry
using Annexin V and PI staining. Apoptotic induction
rates after radiation and sorafenib combination treatment
showed no apparent synergistic increase in any of the
cells, when compared with the values observed after ad-
ministration of each treatment separately in both cell lines
(Table 1).
We investigated the activity of cyclin B1 by western blot
analysis in DLD-1 and HT-29 cell lines. Cells were har-
vested after 12 and 24 h of exposure to sorafenib, radiation
or a combination thereof. While radiation induced expres-
sion of cyclin B1, sorafenib inhibited cyclin B1 expression
Fig. 1. Clonogenic survival curves for radiation plus sorafenib treatment in DLD-1 (a) and HT-29 (b) cells. White
circles, radiation alone; black circles, radiation plus sorafenib (4 uM) treatment. DERs were 1.76 and 1.13 at 0.37.
Bars, SEM of three independent experiments.
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Fig. 3. Expression of cyclin B1 by sorafenib (4 uM) and radiation (6 Gy) in DLD-1 (a) and HT-29 (b) cell lines
by western blot analysis. Ctrl, control; S, sorafenib; R, radiation; RS, combination.
Table 1: Measurements of apoptotic fraction were measured after Annexin V and PI staining using flow cytometry in DLD-1 (A)
and HT-29 (B)
Control Sorafenib 4 uM Radiation 6 Gy Sorafenib 4 uM +Radiation 6 Gy
(A) DLD-1
12 h 1.53 2.57 1.08 0.80
24 h 2.08 4.28 3.03 3.79
36 h 0.63 1.13 1.29 1.40
(B) HT-29
12 h 1.40 4.01 1.11 1.57
24 h 1.54 2.16 1.74 2.16
36 h 0.76 1.14 0.57 1.12
No interval changes were observed among treatment groups until 36 h in both cells. The data represent the average value of three
independent experiments.
Fig. 2. Impact of sorafenib and radiation on cell cycle phase distribution. Radiation (6 Gy) and sorafenib (4 uM) treatment
were significantly higher compared with other treatment groups at 48 h (*, P = 0.037; **, P = 0.016) in DLD-1 (a) and HT-29
cells (b) (one black circle, P = 0.004; two black circles, P = 0.02). Columns, mean values of triplicate samples.
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at all time points. Sorafenib also attenuated expression
when combined with radiation (Fig. 3).
As a measure of radiation-induced DNA damage, we
evaluated the induction of nuclear foci of γ-H2AX, which
has been established as a sensitive indicator of DNA
double strand breaks (DSBs), with the dispersion of foci
corresponding to DSB repair [17]. Immunofluorescent
stains for γ-H2AX foci were determined at 0, 6 and 24 h
after radiation. Both cell lines showed significant γ-H2AX
production at 6 h post-radiation regardless of sorafenib
Fig. 4. Confocal microscopy for detection of γ-H2AX foci. DLD-1 (a) and HT-29 (b) cells on coverslips were treated with 2 Gy ± sorafenib,
and then confocal microscopy was performed to detect γ-H2AX foci (green colored image, right-side) as well as nucleus (blue colored image,
left-side). Measurement of average fluorescence intensity of γ-H2AX foci per cell in DLD-1 (c) and HT-29 (d) cells. The combination group
resulted in a greater number of remaining γ-H2AX foci than radiation alone at 24 h with statistical significances in DLD-1 (*, P < 0.05), and in
HT-29 (black circle, P < 0.05). The plotted data represent the average value and SEM of three independent experiments.
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treatment. However, significant differences of clearance
γ-H2AX were observed between radiation and combination
at 24 h post-radiation (Fig. 4). The combination arm
delayed the clearance of γ-H2AX, suggesting that sorafenib
maintains DNA damage and increases radio-sensitivity.
To measure the proportion of cells that underwent the ab-
errant mitotic process, we counted the number of cells
showing nuclear fragmentation according to sorafenib and/
or radiation treatment. The percentage increased up to 72 h
after radiation. In cells receiving the combination treatment,
a significantly greater number of cells showing nuclear
fragmentation were detected at 48 and 72 h, compared with
radiation alone. Therefore, these data suggest that the
radiation-induced cytotoxicity by sorafenib results in an in-
crease in the number of cells undergoing aberrant mitosis
(Fig. 5).
Tumors were generated at the hind legs of nude mice.
When tumors grew to a mean volume of 166 mm3, mice
were randomized into four groups: mock alone, sorafenib
alone (60 mg/kg by p.o. gavage), irradiation (7.5 Gy/3 frac-
tion/3 consecutive days) alone, and sorafenib plus radiation.
Each experimental group contained eight to ten mice. In
our study, significant tumor growth delay was confirmed
between the sorafenib plus radiation group and all the other
groups in the tumor xenograft model. Sorafenib treatment
alone delayed tumor growth as did sorafenib plus radiation
treatment for the first 5 days, but thereafter tumors rapidly
grew and caught up to the control group on Day 12.
Fractionated radiation treatment with 7.5 Gy produced a
2-day GD. In contrast, the combined treatment of 60 mg/kg
sorafenib and 7.5-Gy fractionated radiation produced a GD
of 7 days. This resulted in an EF of 3.5, indicating more
than just an additive effect for the combination treatment
(Fig. 6).
DISCUSSION
In this study, treatment with sorafenib enhanced the cyto-
toxic effect of radiation. As found in previous reports, post-
radiation sorafenib treatment was more lethal compared
with pre-radiation treatment in colon cancer cell lines.
Sorafenib treatment with radiation exhibited significant
tumor growth delay in an in vivo system [14, 15]. The
mechanism by which radiation-enhancement occurred,
however, appeared to be somewhat more complex than pre-
dicted in previous studies.
The accumulation of the cells in the G2-M phase may
partially explain the higher susceptibility to radiation-
induced DNA damage, reflected in the increase in both
nuclear fragmentations and delayed clearance of γ-H2AX,
compared with cells treated with radiation alone. Because
of DNA repair inhibition by sorafenib and subsequent
chromosomal abnormalities as they go into mitotic stage,
this could explain some of the enhanced radiation-induced
cytotoxicity observed with sorafenib post-incubation.
Likewise, Sorafenib results in downregulation of cyclin B1
after radiation leading to an increase in the percentage of
cells in the G2-M phase of the cell cycle.
The phosphorylation of γ-H2AX in DSBs is regarded as
an early response to various DNA damage including
Fig. 4. (Continued)
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radiation, even though it is not necessary for the initial acti-
vation of DNA damage repair or signal transduction. While
γ-H2AX foci induction is found several minutes after DNA
damage, the inactivation of γ-H2AX foci by phosphatases
occurs over hours to days and reflects the activity of DNA
repair proteins following DSB [16]. Several investigators
have demonstrated the correlation between the persistence
of γ-H2AX and radio-sensitivity in a wide range of cell
lines. Combined treatment with radiation and radio-
sensitizing agents shows effective cytotoxicity and appears
to affect the kinetics of γ-H2AX clearance after radiation.
However, there are conflicting data on the kinetics thereof.
Several studies suggested that suppression of phosphoryl-
ation of γ-H2AX foci by agents can sensitize tumors to
radiation in in vitro and in vivo tumor models [17–19]. The
actions of agents are supposed to either control γ-H2AX
directly or result in γ-H2AX foci inactivation after radiation
by interfering with upstream kinase activity. In contrast,
one report suggested that overexpression of γ-H2AX foci
appeared to sensitize glioma cell lines to radiation, possibly,
Fig. 5. Influence of sorafenib on radiation-induced nuclear fragmentation. DLD-1 (a) and HT-29 (b) cell lines growing in chamber
slides were assigned to control, sorafenib (4 uM), radiation (6 Gy) and combination groups and fixed at 24 h, 48 h and 72 h. Cells were
fixed with 4% paraformaldehyde, and stained with DAPI followed by staining with α-tubulin. Images were taken with a Zeiss LSM 510
Meta confocal microscope. Columns, mean; bars, SE. Nuclear fragmentation was defined as the presence of two or more distinct lobes
within a single cell. *, **, ***, one black circle, two black circles, P < 0.05 according to Student’s t-test.
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by contributing to G2-M arrest [20]. Our data showed
delayed clearance of γ-H2AX foci in combination treatment
compared with radiation alone at 24 h. The addition of sor-
afenib to radiation seems to be associated with delaying
repair of radiation-induced DSB.
Interestingly, sorafenib-treated cells after radiation failed
to undergo the mitotic phase. The block of sorafenib-
mediated cell cycle progression, hence, seems to be due to
failure of the cells to undergo the transition from G2 to M
phase. The failure of the cells to escape from the G2-M
phase seems to be related to the sorafenib-mediated down-
regulation of cyclin B1 levels. When combined with radi-
ation, sorafenib reinforces radiation-induced mitotic arrest
by attenuating cyclin B1. The ability of sorafenib to select-
ively impair the accumulation of cyclin B1 could underlie
its potent radiation-enhancing activity. Exposure of
radiation-arrested cells to sorafenib can hence enhance
nuclear fragmentation and aberrant mitosis. Although much
remains to be clarified regarding the action of sorafenib on
the cell cycle, the ability of sorafenib to reinforce
radiation-induced mitotic arrest has highlighted a potent
and novel antiproliferative activity that may have significant
implications for the targeting of cancerous cells and enhan-
cing radiation response.
In conclusion, exposure of each cell line to sorafenib
combined with radiation resulted in an increase in radio-
response. Sorafenib combined with radiation-induced accu-
mulation of tumor cells in the G2-M phase and also showed
a greater number of remaining γ-H2AX foci and greater
nuclear fragmentation, representing aberrant mitosis, than ra-
diation treatment alone. Sorafenib-mediated down-regulation
of cyclin B1 levels contributed to radiation-induced cell
cycle arrest and DNA damage. Tumor xenograft study con-
firmed that administration of sorafenib results in significant
tumor growth inhibition when combined with radiation.
Sorafenib may be promising as an agent for enhancing radi-
ation response in colorectal cancer. Therefore, clinical trials
are necessary to test the efficacy of radiation with sorafenib.
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